GlassScriptPhysician profile
Lori Dwyer
NPI 1770604282
$5,128.88
in general payments reported to CMS, 2019-2025
25 companies · $1,506 in 2025
The $1,506 reported for 2025 was more than what 90% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $699 · 2022: $595 · 2023: $797 · 2024: $1,532 · 2025: $1,506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,836.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,835.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $991.00 | 2021-2025 | |
| Novo Nordisk INC | $814.18 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $542.76 | 2021-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals LP | $471.12 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $363.81 | 2021-2025 | |
| Astellas Pharma US INC | $353.45 | 2023-2025 | Veozah |
| Abbott Laboratories | $270.37 | 2022-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $252.02 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.13 | 2021-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $170.92 | 2024-2025 | Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $159.06 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $75.75 | 2021-2025 | Lagevrio |
| Shield Therapeutics INC | $64.28 | 2023-2024 | Accrufer |
| Lundbeck LLC | $44.23 | 2021 | |
| Xeris Pharmaceuticals, INC. | $42.04 | 2022-2024 | Keveyis |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $41.14 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $37.94 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $37.64 | 2021-2025 | Eliquis |
| Boston Scientific Corporation | $35.83 | 2023-2024 | Wavewriter Alpha Prime 16 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.06 | 2025 | Caplyta |
| Biohaven Pharmaceuticals, INC. | $31.02 | 2021 | |
| Alexion Pharmaceuticals, INC. | $29.26 | 2024 | Soliris |
| Scilex Pharmaceuticals INC. | $24.24 | 2022 | |
| Dexcom, INC. | $19.86 | 2024 | Dexcom G6 Transmitter |
| Krystal Biotech INC | $19.77 | 2024 | Vyjuvek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Dwyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.